# Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

> **NCT02041234** · PHASE4 · COMPLETED · sponsor: **Khoo Teck Puat Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Type II Diabetes in Subjects BMI 27 to 32

## Interventions

- **PROCEDURE:** Roux-en-Y Gastric Bypass (RYGB)
- **DRUG:** Incretin analogues
- **DRUG:** Xenical
- **DRUG:** SGLT2 inhibitors
- **DRUG:** DPP-4 Inhibitors

## Key facts

- **NCT ID:** NCT02041234
- **Lead sponsor:** Khoo Teck Puat Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2020-12
- **Final completion:** 2022-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041234, "Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02041234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*